Swedish drugmaker Karo Bio (STO: KARO) says it has acquired more than 90% of the shares in MedCore AB, also based in Sweden.
MedCore markets primarily licensed medtech products to pharmacies and hospitals in the Nordic region. The products target the therapeutic areas diabetes, anesthesia/intensive care and surgery. Turnover is around 50 million Swedish kronor ($5.9 million), with an operating profit expected to be slightly positive in 2015.
19 million kronor purchase price
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze